Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. 1997

R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
Laboratory of Chromatography and Separative Techniques, I.R.C.C.S. H San Raffaele, Milano, Italy.

The aim of this study was to set up a method for quantification of plasma mitomycin C (MMC) concentrations during intravesical chemotherapy delivered in the presence of local bladder hyperthermia (HT). In comparison with existing methods, this assay, characterized by relative simplicity and efficiency, resulted in the facilitation of performance with nondedicated instrumentation or nonspecialized staff. Purification from plasma matrix was carried out by solid-phase extraction under vaccuum. The purified drug was then collected directly into the vials of the HPLC autosampler. Chromatographic analysis was performed on a reversed-phase C18 column with water:acetonitrile (85:15 by vol) as the mobile phase and the UV detector set at 365 nm. The use of porfiromycin as internal standard provided a method with good within-day precision (CV 6.0% at 5 micrograms/L, n = 6), linearity (0.5-50 micrograms/L), and specificity. The lower limit of detection (< or = 0.5 microgram/L) proved to be suitable for plasma pharmacokinetics monitoring in two tested patients treated with MMC + HT for superficial bladder cancer.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D016685 Mitomycin An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis. Mitomycin C,Ametycine,Mitocin-C,Mitomycin-C,Mutamycin,NSC-26980,Mitocin C,MitocinC,NSC 26980,NSC26980

Related Publications

R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
January 1989, Biomedical chromatography : BMC,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
January 2015, Journal of chromatographic science,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
August 2000, International journal of pharmaceutics,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
November 1999, Journal of pharmaceutical and biomedical analysis,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
November 2007, Se pu = Chinese journal of chromatography,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
March 1997, Journal of pharmaceutical and biomedical analysis,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
October 2008, Biomedical chromatography : BMC,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
November 2020, Journal of AOAC International,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
October 2002, The Analyst,
R Paroni, and C Arcelloni, and E De Vecchi, and I Fermo, and D Mauri, and R Colombo
January 1987, Biomedical chromatography : BMC,
Copied contents to your clipboard!